Cannabinoid physiology and pharmacology: 30 years of progress

Abood, 1992, Neurobiology of marijuana abuse, Trends Pharmacol. Sci, 13, 201, 10.1016/0165-6147(92)90064-D

Abood, 1993, Development of behavioral tolerance to Δ9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain, Pharmacol. Biochem. Behav, 46, 575, 10.1016/0091-3057(93)90546-6

Adams, 1996, Cannabis: pharmacology and toxicology in animals and humans, Addiction, 91, 1585, 10.1111/j.1360-0443.1996.tb02264.x

Agurell, 1986, Pharmacokinetics and meta bolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man, Pharmacol. Rev, 38, 21

Alger, 2002, Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids, Prog. Neurobiol, 68, 247, 10.1016/S0301-0082(02)00080-1

Alger, 1996, Retrograde signalling in depolarization-induced suppression of inhibition in rat hippocampal CA1 cells, J. Physiol, 496, 197, 10.1113/jphysiol.1996.sp021677

Barth, 1999, The development of cannabinoid antagonists, Curr. Med. Chem, 6, 745, 10.2174/0929867306666220401143808

Bayewitch, 1995, The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling, FEBS Lett, 375, 143, 10.1016/0014-5793(95)01207-U

Beau, 1998, Transient suppression of GABA-A-receptor-mediated IPSPs after epileptiform burst discharges in CB1 pyramidal cells, J. Neurophysiol, 79, 659, 10.1152/jn.1998.79.2.659

Bidaut-Russell, 1990, Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain, J. Neurochem, 55, 21, 10.1111/j.1471-4159.1990.tb08815.x

Biegon, 2001, Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain, Neuroimage, 14, 1463, 10.1006/nimg.2001.0939

Black, 2004, Cannabinoid receptor antagonists and obesity, Curr. Opin. Investig. Drugs, 5, 389

Bloom, 1997, Cannabinoid-induced alterations in regional cerebral blood flow in the rat, Pharmacol. Biochem. Behav, 57, 625, 10.1016/S0091-3057(96)00475-3

Bornheim, 1989, Effect of cannabidiol on cytochrome P-450 isozymes, Biochem. Pharmacol, 38, 2789, 10.1016/0006-2952(89)90432-2

Bornheim, 1993, The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism, Biochem. Biophys. Res. Commun, 197, 740, 10.1006/bbrc.1993.2541

Bouaboula, 1995, Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1, Biochem. J, 312, 637, 10.1042/bj3120637

Bouaboula, 1996, Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression, Eur. J. Biochem, 237, 704, 10.1111/j.1432-1033.1996.0704p.x

Breivogel, 1997, Regional differences in cannabinoid receptor/G-protein coupling in rat brain, J. Pharmacol. Exp. Ther, 282, 1632

Breivogel, 1998, Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity, J. Biol. Chem, 273, 16865, 10.1074/jbc.273.27.16865

Breivogel, 1999, Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain, J. Neurochem, 73, 2447, 10.1046/j.1471-4159.1999.0732447.x

Breivogel, 2001, Evidence for a new G protein-coupled cannabinoid receptor in mouse brain, Mol. Pharmacol, 60, 155, 10.1124/mol.60.1.155

Burkey, 1997, Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain, Eur. J. Pharmacol, 336, 295, 10.1016/S0014-2999(97)01255-7

Burkey, 1997, Δ9-Tetrahydrocannabinol is a partial agonist of can nabinoid receptors in mouse brain, Eur. J. Pharmacol, 323, R3, 10.1016/S0014-2999(97)00146-5

Burstein, 1991, Detection of cannabinoid receptors by photoaffinity labelling, Biochem. Biophys. Res. Commun, 176, 492, 10.1016/0006-291X(91)90951-3

Burstein, 1994, Phospholipase participation in cannabinoid-induced release of free arachidonic acid, Biochem. Pharmacol, 48, 1253, 10.1016/0006-2952(94)90163-5

Buzsaki, 1998, Memory consolidation during sleep: a neurophysiological perspective, J. Sleep Res, 7, 17, 10.1046/j.1365-2869.7.s1.3.x

Cabral, 1998, Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease, J. Neuroimmunol, 83, 116, 10.1016/S0165-5728(97)00227-0

Cadas, 1996, Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP, J. Neurosci, 16, 3934, 10.1523/JNEUROSCI.16-12-03934.1996

Calignano, 2001, Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide, Eur. J. Pharmacol, 419, 191, 10.1016/S0014-2999(01)00988-8

Carlson, 2002, Endocannabinoids facilitate the induction of LTP in the hippocampus, Nat. Neurosci, 5, 723, 10.1038/nn879

Caulfield, 1992, Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism, Br. J. Pharmacol, 106, 231, 10.1111/j.1476-5381.1992.tb14321.x

Childers, 1993, Cannabinoid receptors: G-protein-mediated signal transduction mechanisms, Biochem. Soc. Symp, 59, 27

Cohen, 2002, SR141716, a central cannabinoid (CB) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats, Behav. Pharmacol, 13, 451, 10.1097/00008877-200209000-00018

Compton, 1992, Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from Δ9-tetrahydrocannabinol, J. Pharmacol. Exp. Ther, 263, 1118

Compton, 1993, Cannabinoid structure-ctivity relationships: correlation of receptor binding and in vivo activities, J. Pharmacol. Exp. Ther, 265, 218

Consroe, 1987, Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers, NIDA Res. Monogr, 79, 59

Csicsvari, 2000, Ensemble patterns of hippocampal CA3-CA1 neurons during sharp wave-associated population events, Neuron, 28, 585, 10.1016/S0896-6273(00)00135-5

Daniel, 2004, Mechanisms underlying cannabinoid inhibition of presynaptic Ca2+ influx at parallel fibre synapses of the rat cerebellum, J. Physiol, 557, 159, 10.1113/jphysiol.2004.063263

De Vries, 2001, A cannabinoid mechanism in relapse to cocaine seeking, Nat. Med, 7, 1151, 10.1038/nm1001-1151

De Vries, 2003, Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats, Psychopharmacology (Berlin), 168, 164, 10.1007/s00213-003-1422-1

Deadwyler, 2004, Differential but complementary mnemonic functions of the hippocampus and subiculum, Neuron, 42, 465, 10.1016/S0896-6273(04)00195-3

Deadwyler, 1993, Cannabinoids modulate potassium current in cultured hippocampal neurons, Receptors Channels, 1, 121

Deadwyler, 1995, Complete adaptation to the memory disruptive effects of delta-9-THC following 35 days of exposure, Neurosci. Res. Commun, 17, 9

Devane, 1988, Determination and characterization of a cannabinoid receptor in rat brain, Mol. Pharmacol, 34, 605

Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919

Dewey, 1986, Cannabinoid pharmacology, Pharmacol. Rev, 38, 151

Dill, 1988, Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs, J. Pharmacol. Exp. Ther, 244, 1157

DiMarzo, 1999, Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids, Curr. Med. Chem, 6, 721, 10.2174/0929867306666220401141630

DiMarzo, 2000, Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain, J. Neurochem, 75, 2434, 10.1046/j.1471-4159.2000.0752434.x

Duarte, 2004, Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior, Neuropsychopharmacology, 29, 911, 10.1038/sj.npp.1300370

Egertova, 2000, Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB, J. Comp Neurol, 422, 159, 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1

Egertova, 1998, A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain, Proc. R. Soc. Lond B Biol. Sci, 265, 2081, 10.1098/rspb.1998.0543

Fan, 1996, Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice, Brain Res, 706, 13, 10.1016/0006-8993(95)01113-7

Felder, 1995, Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors, Mol. Pharmacol, 48, 443

Fernandez, 2004, Rimonabant Sanofi-Synthelabo, Curr. Opin. Investig. Drugs, 5, 430

Freedland, 2002, Dose-dependent effects of Δ9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat, Synapse, 45, 134, 10.1002/syn.10089

Freedland, 2003, Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study, Brain Res, 962, 169, 10.1016/S0006-8993(02)03999-9

Freund, 2003, Role of endogenous cannabinoids in synaptic signaling, Physiol. Rev, 83, 1017, 10.1152/physrev.00004.2003

Giuffrida, 2001, Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology, J. Pharmacol. Exp. Ther, 298, 7

Glass, 1997, Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor, J. Neurosci, 17, 5327, 10.1523/JNEUROSCI.17-14-05327.1997

Glass, 1997, Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain, Neuroscience, 77, 299, 10.1016/S0306-4522(96)00428-9

Goldman, 1975, Δ9-Tetrahydrocannabinol alters flow of blood to subcortical areas of the conscious rat brain, Life Sci, 17, 477, 10.1016/0024-3205(75)90500-7

Hampson, 1999, Distribution of spatial and nonspatial information in dorsal hippocampus, Nature, 402, 610, 10.1038/45154

Hampson, 2001, What ensemble recordings reveal about functional hippocampal cell encoding, Prog. Brain Res, 130, 345, 10.1016/S0079-6123(01)30023-7

Hampson, 2002, “Keeping on track”: firing of hippocampal neurons during delayed-nonmatch-to-sample performance, J. Neurosci, 22, RC198, 10.1523/JNEUROSCI.22-02-j0002.2002

Hampson, 2003, Functional significance of cannabinoid-mediated, depolarization-induced suppression of inhibition (DSI) in the hippocampus, J. Neurophysiol, 90, 55, 10.1152/jn.01161.2002

Henry, 1995, Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes, Neurosci. Lett, 186, 91, 10.1016/0304-3940(95)11289-9

Herkenham, 1991, Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study, J. Neurosci, 11, 563, 10.1523/JNEUROSCI.11-02-00563.1991

Hollister, 1986, Health aspects of cannabis, Pharmacol. Rev, 38, 1

Houston, 1993, Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins, Mol. Pharmacol, 43, 17

Howlett, 1984, Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds, Life Sci, 35, 1803, 10.1016/0024-3205(84)90278-9

Howlett, 1985, Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes, Mol. Pharmacol, 27, 429

Howlett, 2002, The cannabinoid receptors, Prostaglandins Other Lipid Mediat, 68-9, 619, 10.1016/S0090-6980(02)00060-6

Howlett, 1984, Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes, Mol. Pharmacol, 26, 532

Howlett, 1986, Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs, Mol. Pharmacol, 29, 307

Howlett, 1990, Stereochemical effects of 11-OH-Δ8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor, Neuropharmacology, 29, 161, 10.1016/0028-3908(90)90056-W

Howlett, 1995, Cannabinoid receptor agonists and antagonists, Curr. Pharm. Des, 1, 343, 10.2174/1381612801666220918164118

Howlett, 2002, International Union of Pharmacology. XXVII. Classification of cannabinoid receptors, Pharmacol. Rev, 54, 161, 10.1124/pr.54.2.161

Huffman, 1999, Cannabimimetic indoles, pyrroles and indenes, Curr. Med. Chem, 6, 705, 10.2174/0929867306666220401125055

Jarai, 1999, Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors, Proc. Natl. Acad. Sci. USA, 96, 14136, 10.1073/pnas.96.24.14136

Johnson, 1981, Selective and potent analgetics derived from cannabinoids, J. Clin. Pharmacol, 21, 271S, 10.1002/j.1552-4604.1981.tb02605.x

Katona, 1999, Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons, J. Neurosci, 19, 4544, 10.1523/JNEUROSCI.19-11-04544.1999

Katona, 2001, Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission, J. Neurosci, 21, 9506, 10.1523/JNEUROSCI.21-23-09506.2001

Kim, 2002, Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus, J. Neurosci, 22, 10182, 10.1523/JNEUROSCI.22-23-10182.2002

Kuster, 1993, Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids, J. Pharmacol. Exp. Ther, 264, 1352

Lallemand, 2001, Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration, Alcohol Clin. Exp. Res, 25, 1317, 10.1111/j.1530-0277.2001.tb02353.x

Landsman, 1997, SR141716A is an inverse agonist at the human cannabinoid CB1 receptor, Eur. J. Pharmacol, 334, R1, 10.1016/S0014-2999(97)01160-6

Lenz, 1999, Calcium dependence of depolarization-induced suppression of inhibition in rat hippocampal CA1 pyramidal neurons, J. Physiol, 521, 147, 10.1111/j.1469-7793.1999.00147.x

Mackie, 1992, Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells, Proc. Natl. Acad. Sci. USA, 89, 3825, 10.1073/pnas.89.9.3825

Mackie, 1993, Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells, Mol. Pharmacol, 44, 498

Mackie, 1995, Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor, J. Neurosci, 15, 6552, 10.1523/JNEUROSCI.15-10-06552.1995

Mailleux, 1992, Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry, Neuroscience, 48, 655, 10.1016/0306-4522(92)90409-U

Maneuf, 1997, Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices, Br. J. Pharmacol, 120, 1397, 10.1038/sj.bjp.0701101

Margulies, 1991, Δ9-Tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain, Eur. J. Pharmacol, 202, 373, 10.1016/0014-2999(91)90281-T

Marsicano, 2002, The endogenous cannabinoid system controls extinction of aversive memories, Nature, 418, 530, 10.1038/nature00839

Martin, 1986, Cellular effects of cannabinoids, Pharmacol. Rev, 38, 45

Martin, 1999, Discovery and characterization of endogenous cannabinoids, Life Sci, 65, 573, 10.1016/S0024-3205(99)00281-7

Mechoulam, 1970, Marihuana chemistry, Science, 168, 1159, 10.1126/science.168.3936.1159

Mechoulam, 1967, The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish, Tetrahedron Lett, 12, 1109, 10.1016/S0040-4039(00)90646-4

Mechoulam, 2001, The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection, Pain Res. Manag, 6, 67, 10.1155/2001/183057

Mechoulam, 1967, A stereospecific synthesis of (−)-delta 1- and (−)-delta 1(6)-tetrahydrocannabinols, J. Am. Chem. Soc, 89, 4552, 10.1021/ja00993a072

Mechoulam, 1995, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem. Pharmacol, 50, 83, 10.1016/0006-2952(95)00109-D

Moldrich, 2000, Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study, Peptides, 21, 1735, 10.1016/S0196-9781(00)00324-7

Morishita, 1998, Evidence for metabotropic glutamate receptor activation in the induction of depolarization-induced suppression of inhibition in hippocampal CA1, J. Neurosci, 18, 4870, 10.1523/JNEUROSCI.18-13-04870.1998

Mukhopadhyay, 2002, Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent, Am. J. Physiol. Heart Circ. Physiol, 282, H2046, 10.1152/ajpheart.00497.2001

Offertaler, 2003, Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor, Mol. Pharmacol, 63, 699, 10.1124/mol.63.3.699

Oviedo, 1993, Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study, Brain Res, 616, 293, 10.1016/0006-8993(93)90220-H

Pacheco, 1991, Aminoalkylindoles: actions on specific G-protein-linked receptors, J. Pharmacol. Exp. Ther, 257, 170

Pacheco, 1993, Identification of cannabinoid receptors in cultures of rat cerebellar granule cells, Brain Res, 603, 102, 10.1016/0006-8993(93)91304-B

Pacheco, 1994, Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes, J. Neurochem, 62, 1773, 10.1046/j.1471-4159.1994.62051773.x

Pertwee, 1988, The central neuropharmacology of psychotropic cannabinoids, Pharmacol. Ther, 36, 189, 10.1016/0163-7258(88)90106-4

Pertwee, 1999, Pharmacology of cannabinoid receptor ligands, Curr. Med. Chem, 6, 635, 10.2174/0929867306666220401124036

Pertwee, 2000, Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development, Expert. Opin. Investig. Drugs, 9, 1553, 10.1517/13543784.9.7.1553

Pertwee, 1993, Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide, Br. J. Pharmacol, 110, 1483, 10.1111/j.1476-5381.1993.tb13989.x

Pettit, 1998, Immunohistochemical localization of the neural cannabinoid receptor in rat brain, J. Neurosci. Res, 51, 391, 10.1002/(SICI)1097-4547(19980201)51:3<391::AID-JNR12>3.0.CO;2-A

Piomelli, 2003, The molecular logic of endocannabinoid signalling, Nat. Rev. Neurosci, 4, 873, 10.1038/nrn1247

Pitler, 1994, Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism, Neuron, 13, 1447, 10.1016/0896-6273(94)90430-8

Poncelet, 2003, Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice, Neurosci. Lett, 343, 216, 10.1016/S0304-3940(03)00397-5

Pontieri, 1999, Metabolic mapping of the effects of WIN 55212-2 intravenous administration in the rat, Neuropsychopharmacology, 21, 773, 10.1016/S0893-133X(99)00064-0

Prather, 2000, Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies, Mol. Pharmacol, 57, 1000

Razdan, 1986, Structure-ctivity relationships in cannabinoids, Pharmacol. Rev, 38, 75

Reggio, 2000, Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase, Chem. Phys. Lipids, 108, 15, 10.1016/S0009-3084(00)00185-7

Rinaldi-Carmona, 1994, SR141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett, 350, 240, 10.1016/0014-5793(94)00773-X

Rinaldi-Carmona, 1998, SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor, J. Pharmacol. Exp. Ther, 284, 644

Rodriguez de Fonseca, 1991, Effects of Δ9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments, Pharmacol. Biochem. Behav, 40, 593, 10.1016/0091-3057(91)90368-C

Rodriguez de Fonseca, 1994, Downregulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment, Pharmacol. Biochem. Behav, 47, 33, 10.1016/0091-3057(94)90108-2

Romero, 1995, Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Δ9-tetrahydrocannabinol, Pharmacol. Biochem. Behav, 51, 731, 10.1016/0091-3057(95)00023-P

Romero, 1997, Effects of chronic exposure to Δ9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions, Brain Res. Mol. Brain Res, 46, 100, 10.1016/S0169-328X(96)00277-X

Schmid, 2000, Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively?, Chem. Phys. Lipids, 108, 71, 10.1016/S0009-3084(00)00188-2

Selley, 1996, Cannabinoid receptor stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding in rat brain membranes, Life Sci, 59, 659, 10.1016/0024-3205(96)00347-5

Selley, 1997, mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy, Mol. Pharmacol, 51, 87, 10.1124/mol.51.1.87

Shen, 1996, Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures, J. Neurosci, 16, 4322, 10.1523/JNEUROSCI.16-14-04322.1996

Shivachar, 1996, Anandamide- and Δ9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride], Biochem. Pharmacol, 51, 669, 10.1016/S0006-2952(95)02248-1

Sim, 1996, Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPγS autoradiography in rat brain, J. Neurosci, 16, 8057, 10.1523/JNEUROSCI.16-24-08057.1996

Sim, 1996, Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum, Eur. J. Pharmacol, 307, 97, 10.1016/0014-2999(96)00211-7

Sim-Selley, 2004, Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids, Crit. Rev. Neurobiol, 15, 91, 10.1615/CritRevNeurobiol.v15.i2.10

Sim-Selley, 2002, Neuroanatomical localization of receptor-activated G proteins in brain, Methods Enzymol, 344, 42, 10.1016/S0076-6879(02)44704-0

Slipetz, 1995, Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase, Mol. Pharmacol, 48, 352

Stein, 1998, Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat, Neuropsychopharmacology, 19, 481, 10.1016/S0893-133X(98)00043-8

Stella, 1997, A second endogenous cannabinoid that modulates long-term potentiation, Nature, 388, 773, 10.1038/42015

Sugiura, 2000, 2-Arachidonoylglycerol and the cannabinoid receptors, Chem. Phys. Lipids, 108, 89, 10.1016/S0009-3084(00)00189-4

Sugiura, 1995, 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain, Biochem. Biophys. Res. Commun, 215, 89, 10.1006/bbrc.1995.2437

Tsou, 1998, Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system, Neuroscience, 83, 393, 10.1016/S0306-4522(97)00436-3

Twitchell, 1997, Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons, J. Neurophysiol, 78, 43, 10.1152/jn.1997.78.1.43

van der Stelt, 2003, The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders, Eur. J. Pharmacol, 480, 133, 10.1016/j.ejphar.2003.08.101

Varma, 2001, Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus, J. Neurosci, 21, RC188, 10.1523/JNEUROSCI.21-24-j0003.2001

Varma, 2002, Presynaptic factors in the regulation of DSI expression in hippocampus, Neuropharmacology, 43, 550, 10.1016/S0028-3908(02)00168-5

Wagner, 1999, Mesenteric vasodilation mediated by endothelial anandamide receptors, Hypertension, 33, 429, 10.1161/01.HYP.33.1.429

Whitlow, 2002, Metabolic mapping of the time-dependent effects of Δ9-tetrahydrocannabinol administration in the rat, Psychopharmacology (Berlin), 161, 129, 10.1007/s00213-002-1001-x

Wilson, 1975, Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs, J. Med. Chem, 18, 700, 10.1021/jm00241a012

Wilson, 2001, Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses, Nature, 410, 588, 10.1038/35069076

Wilson, 2002, Endocannabinoid signaling in the brain, Science, 296, 678, 10.1126/science.1063545

Wilson, 2001, Presynaptic specificity of endocannabinoid signaling in the hippocampus, Neuron, 31, 453, 10.1016/S0896-6273(01)00372-5

Yesavage, 1985, Carry-over effects of marijuana intoxication on aircraft pilot performance: a preliminary report, Am. J. Psychiatry, 142, 1325, 10.1176/ajp.142.11.1325

Zhuang, 2003, Lack of functional presynaptic, but putative postsynaptic actions of cannabinoids in hippocampal neurons, Soc. Neurosci. Abstracts, 29, 462

Zygmunt, 1999, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide, Nature, 400, 452, 10.1038/22761